Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2025 06:23 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
November 06, 2025 06:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all...
October 30, 2025 23:02 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global...
October 17, 2025 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
October 14, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
October 13, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis, following program and clinical data review by its independent...
September 12, 2025 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and...
September 02, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality4FRONT-1 Phase 3 trial enrollment continues to exceed expectations, with enrollment...
August 25, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
August 15, 2025 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...